IngredientsAscorbigen (commonly abbreviated ABG) is a naturally occurring bioactive phytochemical belonging to the broad class of indole-derived glucosinolate breakdown products. Chemically, it is an indolyl carbohydrate that consists of (3aS,6S,6aR)-3,3a,6-trihydroxy-3-tetrahydrofuro[3,2-b]furan-2-one in which position 3 is substituted by an indol-3-ylmethyl group. In more accessible terms, ascorbigen (ABG) is a natural compound formed from the condensation of L-ascorbic acid and indole-3-carbinol, and is predominantly found in Brassica vegetables.
Ascorbigen (ABG) belongs to the glucosinolate family and occurs mainly in Brassica vegetables. While ascorbic acid (Vitamin C) is mostly known as a cofactor for proline hydroxylase and as a biological antioxidant, it also forms covalent bonds with natural products. A number of natural products containing an ascorbate moiety have been isolated and characterized from a variety of biological sources, ranging from marine algae to flowering plants. The most studied and recognized of these ascorbylated natural products is the glucobrassicin-derived ascorbigen (ABG), which is found in cruciferous vegetables belonging to Brassica (broccoli, cauliflower, cabbage, etc.).
Several structural analogs of ABG have been identified. Derivatives of ABG have also been found in various Brassica species, including 4-hydroxyascorbigen, 4-methoxyascorbigen, and (the N-methoxy derivative) neoascorbigen.
Ascorbigen is formed from 3-indolylmethylisothiocyanate (or indole-3-carbinol) and ascorbic acid in Brassica vegetables including cabbage, broccoli, cauliflower, and Chinese cabbage. Critically, ascorbigen is not present in intact plant tissue but is formed rapidly when plant cells are damaged, allowing the enzyme myrosinase to hydrolyze glucobrassicin.
An HPLC method has been used to determine ABG precursors, glucobrassicin (GB) and L-ascorbic acid (AA), in intact plant tissues of four nutritionally important vegetable crops belonging to the genus Brassica — white cabbage, cauliflower, Chinese cabbage, and broccoli. The levels of GB varied within the range 25–142 mg kg–1 and AA contents varied within the range 110–840 mg kg–1. The amounts of ABG in homogenized Brassica vegetables were found to be between 7 mg kg–1 and 18 mg kg–1.
The level of GB in the plant material was shown to be the limiting factor in the process of ABG formation. Calculated conversion values expressing the conversion of GB into ABG revealed that only 20–46% of GB present in intact plant tissues was employed in the process of ABG formation.
ABG concentrations can range from 5.3 mg/kg to 16 mg/kg depending on the variety, while the total content of glucobrassicin and its analogs can range from 100 to 1500 mg/kg.
Ascorbigen is particularly enriched in fermented Brassica preparations. During cabbage fermentation, glucobrassicin is hydrolyzed into indol-3-carbinol (I3C) by myrosinase and, as the pH decreases, this indole compound reacts nonenzymatically with ascorbic acid to yield ascorbigen (ABG). Studies have shown that ABG is the main glucosinolate breakdown compound in sauerkraut, and it is present at levels between 3 and 18 μmol/100 g fw.
The formation of ascorbigen is a multi-step enzymatic and spontaneous chemical process triggered by physical disruption of plant tissue. The glucosinolate glucobrassicin is degraded by myrosinase to the corresponding isothiocyanate, which forms indole-3-carbinol by elimination of thiocyanate and water addition to the resulting 3-methylene-3H-indolium intermediate. ABG is produced when ascorbate reacts with the methylene-3H-indolium intermediate, either directly or, more likely, via indole-3-carbinol.
Experiments carried out in model solutions simulating in vitro conditions during vegetable processing indicated the increasing rate of ascorbigen formation with decreasing pH of solution. Ascorbigen was shown to be very labile at higher temperatures and its enhanced stability in acidic medium was evident. The subsequent concentration of ascorbigen is dependent on the levels of its precursors, glucobrassicin (GB) and L-ascorbic acid (Vitamin C), as well as the pH and temperature of the medium.
Early work in the 1960s traced the biogenetic origin of the indole moiety of ascorbigen to the amino acid tryptophan. In view of the fact that the indole moiety of ascorbigen possesses a carbon skeleton identical with that of tryptophan, the hypothesis was put forward that this amino acid may be the precursor of the synthesis in vivo of ascorbigen. In preliminary experiments, the level of ascorbigen in kohlrabi was raised after the injection of tryptophan into the bulb.
Ascorbigen as an isolated or named compound is a product of modern phytochemistry, first characterised in the mid-twentieth century. However, humans have consumed this compound as part of diets rich in Brassica vegetables throughout recorded history. Cruciferous (Brassicaceae) vegetables comprise many important species cultivated worldwide and utilized traditionally for culinary and medicinal purposes in different cultures. In the last couple of decades, growing scientific evidence has suggested that consumption of cruciferous vegetables has a preventive role against a variety of human diseases.
Cabbage (Brassica oleracea) is one of the oldest vegetables known and widely distributed over the world among cultivated plants; it was cultivated from ancient times and used both as food and in herbal medicine.
Fermented cabbage preparations — which contain the highest concentrations of ascorbigen among commonly consumed foods — have a long and culturally diverse history. Cabbage is fermented under different names throughout many cultures: as sauerkraut in the U.S., Europe, and Australia, kimchi in Korea and East Asia, suan cai in China, and curtido in El Salvador. Historically, sauerkraut can be traced back to the first century A.D.
Among the fermented Brassica products, sauerkraut is a well-known traditional food made from shredded, brined white cabbage and it is commonly consumed in Europe. Fermentation results in complete degradation of glucosinolates and increased contents of health-promoting compounds, including sulforaphane, ABG and I3C.
It is important to clarify that traditional use of Brassica foods and fermented preparations was not premised on any knowledge of ascorbigen specifically, but rather on the general health-promoting properties attributed to these foods across many cultures. Ascorbigen was not identified as a discrete compound until the mid-twentieth century, and its role as a contributor to the observed biological properties of cruciferous vegetables has been an area of scientific investigation only since the late twentieth century. Searches for the natural compounds that determine the anticarcinogenic properties of a cruciferous-vegetable diet revealed the products of alkaloid glucobrassicin biotransformations; among these, ascorbigen, an indole-containing derivative of L-ascorbic acid, was found to be the most abundant.
Ascorbigen is itself the primary active compound under study, but its biological effects in vivo are substantially shaped by the transformation products it generates under the different pH environments encountered in the body.
Study of the chemical properties of ascorbigen showed that it is capable of different transformations in acidic (including gastric juice) and slightly alkaline (including blood) media. The stable and unstable products of ascorbigen transformation determine the biological properties of the compound.
The degradation of ABG in acidic medium causes a release of L-ascorbic acid and a formation of methylideneindolenine; in more alkaline medium, the degradation of ABG causes the formation of 1-deoxy-1-(3-indolyl)-α-L-sorbopyranose and 1-deoxy-1-(3-indolyl)-α-L-tagatopyranose.
A particularly notable transformation product is formed in the stomach. The most important product of ascorbigen transformation in gastric juice is 5,11-dihydroindolo[3,2-b]-carbazole, with a binding affinity to the Ah receptor only 3.7 × 10−2 lower than that of tetrachlorodibenzodioxin. This compound may be responsible for modifying P450 enzyme activities.
Investigations demonstrated a transformation of ABG in mild alkaline media into indole-derived carbohydrates 1-deoxy-1-(3-indolyl)-α-L-sorbopyranose and 1-deoxy-1-(3-indolyl)-α-L-tagatopyranose, resulting from the opening of the lactone ring and decarboxylation. Recent investigations in bovine blood serum and mouse liver homogenates revealed that these 1-deoxy-1-(indol-3-yl)-ketoses are the main products of ABG transformation in vivo.
Thermal processing significantly affects ABG content and its conversion to other bioactive compounds. The changes during boiling are mainly caused by leaching of ascorbigen predominating in cabbage into cooking water and by its thermal hydrolysis. Ascorbigen losses resulting from thermal hydrolysis accounted for 30% after 10 min of boiling and for 90% after 60 min of boiling. One of the ascorbigen breakdown products is indole-3-carbinol; the decrease in ascorbigen content was accompanied by a drastic increase in the content of 3,3′-diindolylmethane, a condensation product of indole-3-carbinol. After 40 and 50 min of boiling, the total content of 3,3′-diindolylmethane in cabbage and cooking water was approximately 0.2 μmol/100 g and was 6-fold higher than that in uncooked cabbage.
By contrast, ascorbigen was found to be stable at acidic pH in both sauerkraut and sauerkraut juice, even after being stored for an extended period. This helps explain why fermented cabbage preparations preserve substantially higher ABG concentrations compared with cooked Brassica foods.
The primary and most well-characterised molecular mechanism of ascorbigen (and particularly its gastric acid transformation products) is activation of the aryl hydrocarbon receptor (AhR). The aryl hydrocarbon receptor (AhR) is a ligand-activated transcription factor involved in regulating a wide range of biological responses. A diverse array of xenobiotics and endogenous small molecules bind to the receptor and drive unique phenotypic responses.
In acidic environments, such as the stomach, ascorbigen is converted into potent ligands for the Aryl Hydrocarbon Receptor (AhR), initiating signaling cascades involved in xenobiotic metabolism and immune response.
The scope of ligands that bind the AhR includes endogenous compounds including multiple tryptophan metabolites, other endogenous biochemicals, pharmaceuticals, and health-promoting phytochemicals including flavonoids, indole-3-carbinol and its metabolites. ABG and its acid-derived products fall into this latter category.
AhR activation can modulate both xenobiotic metabolism and tumor biology, though these effects are highly context-dependent. The expression and activation of AhR can inhibit the proliferation, migration, and survival of cancer cells, and many clinically approved drugs transcriptionally activate AhR. However, similar AhR ligands exert variable anticancer or cancer-promoting potential in a cell- and tissue-specific mode of action.
Indoles produced from glucosinolate hydrolysis are able to influence phase I and phase II biotransformation enzyme activities, thereby possibly influencing several processes related to chemical carcinogenesis, including the metabolism, DNA-binding, and mutagenic activity of promutagens. The acid-derived transformation products of ABG, by acting as AhR ligands, can trigger the gene battery regulated by the AhR, which includes cytochrome P450 enzymes (especially CYP1 family members) and various phase II detoxification enzymes.
The anticarcinogenic properties of ABG due to its ability to induce activation of xenobiotic-metabolizing enzymes and apoptosis of tumoral cells have been documented in the scientific literature.
The antioxidative properties of ascorbigen, one of the major indole-derived compounds of Brassica vegetables, were systematically evaluated using multiple assay systems. Assays using model radicals included the DPPH radical, galvinoxyl radical, and ABTS radical cation (ABTS•+). Ascorbigen showed stronger activity than that of ascorbic acid in the ABTS•+-scavenging assay but showed no activity in the DPPH radical- and galvinoxyl radical-scavenging assays. In the ABTS•+-scavenging assay, the indole moiety of ascorbigen contributed to scavenging of the radicals to produce indole-3-aldehyde as one of the final reaction products.
While its biological activities, including anticarcinogenic and immunomodulatory effects, are of significant interest, its role as an antioxidant has been a subject of detailed investigation. Importantly, one study found that ascorbigen does not activate the Nrf2 transcription factor. Sulforaphane but not ascorbigen, indole-3-carbinol, and ascorbic acid activates the transcription factor Nrf2 and induces phase-2 and antioxidant enzymes in human keratinocytes in culture. This distinguishes ABG mechanistically from the closely related Brassica compound sulforaphane.
Ascorbigen (ABG), a natural compound formed from the breakdown of glucobrassicin in Brassica vegetables, is emerging as a significant immunomodulatory agent. Its immunomodulatory function appears to be substantially mediated through AhR activation, which influences immune cell differentiation, cytokine production, and regulatory T cell induction — pathways that are the subject of active, ongoing investigation.
In vitro pharmacological studies revealed additional mechanisms. One study tested the hypothesis that ascorbigen demonstrates antioxidant properties and protects human umbilical cord endothelial cells against hyperglycemic toxicity in vitro. It was observed that ascorbigen, in micromolar concentrations, protected against endothelial cell death from glucose toxicity. Additionally, ascorbigen at 3.0 mM shifted the concentration response curve of L-phenylephrine to the right, with a reduction in the maximal contractile effects of the agonist. This action was not related to alpha-adrenoceptor blockade. Ascorbigen also relaxed the vascular tone induced by L-phenylephrine, which is not mediated by an endothelial cell nitric oxide-dependent mechanism. On the guinea-pig ileum, the spasmogenic effects of carbachol, histamine, and serotonin were reduced in the presence of 3 mM ascorbigen. Spasm of the gut induced by the acetylcholinesterase inhibitor physostigmine was antagonized by ascorbigen with an IC50 of 286 μM.
The most extensively researched potential application of ascorbigen is in the area of cancer chemoprevention, largely studied in preclinical (animal and cell-based) models.
ABG may partly mediate the known anticarcinogenic effect of diets rich in Brassicaceae. Brassicas, including all types of cabbages, broccoli, cauliflower, and Brussels sprouts, may be protective against cancer due to their relatively high glucosinolate content. Glucosinolates are usually broken down through hydrolysis catalyzed by myrosinase, an enzyme that is released from damaged plant cells.
ABG has been shown in animal studies to have an anticarcinogenic effect. A reducing effect on tumor formation has been shown in rats and mice. However, direct human clinical trials isolating ABG's specific anticancer effects are lacking. Most available evidence is from epidemiological studies on Brassica-rich diets, animal experiments, and cell culture models.
Experiments have shown that high quantities of glucosinolates, ascorbigen, and ascorbic acid reduce DNA damage and cell mutation rate in cancer patients, and sauerkraut is known to have these substances in abundance. This citation reflects an association observed in one study context, not the result of a controlled clinical trial specifically attributing effects to ABG.
Evidence strength: Preliminary. Evidence is predominantly animal- and in vitro-based, with no dedicated human clinical trials. Epidemiological associations between cruciferous vegetable intake and reduced cancer risk exist but cannot be attributed specifically to ABG.
One published human clinical trial — though small and preliminary — specifically investigated ABG in a clinical population. Twelve female fibromyalgia syndrome (FMS) patients were given 500 mg per day of a blend containing 100 mg ascorbigen and 400 mg broccoli powder in a preliminary, one-month, open-label trial. This group of patients showed a mean 20.1 percent (p=0.044) decrease in their physical impairment score and a mean 17.8 percent (p=0.016) decrease in their total fibromyalgia impact scores as measured by the Fibromyalgia Impact Questionnaire.
The mean physical impairment score two weeks post-treatment showed a significant return to near pre-treatment level (p=0.028). Analysis of ten of the patients' mean threshold pain levels at the 18 possible tender points obtained before and at the end of treatment showed a strong trend toward an increase in the mean threshold pain level (p=0.059).
The reduced sensitivity to pain and improvement in quality of life measured in this study appear to be clinically relevant and a larger, double-blind study is warranted.
Evidence strength: Very weak. This is a single, small (n=12), open-label, uncontrolled trial using a combination product (ABG plus broccoli powder). No placebo group, no blinding, and a heterogeneous preparation make it impossible to attribute effects specifically to ABG. The study was described as preliminary by its own authors, who called for a larger controlled trial. No such follow-up trial has been published in the indexed literature.
A study tested the hypothesis that ascorbigen demonstrates antioxidant properties and protects human umbilical cord endothelial cells against hyperglycemic toxicity in vitro. It was observed that ascorbigen, in micromolar concentrations, protected against endothelial cell death from glucose toxicity. The cytoprotective effects of ascorbigen may be highly relevant in the optimum physiological regulation of function, and the therapeutic value of this substance in disease settings needs to be further investigated.
Evidence strength: Weak. Evidence is exclusively from in vitro cell culture models. No animal or human studies have examined vascular or endothelial effects of ABG in vivo.
As detailed under mechanisms, ascorbigen demonstrates selective antioxidant activity in assay systems dependent on the specific radical species tested. Ascorbigen showed stronger activity than that of ascorbic acid in the ABTS•+-scavenging assay but showed no activity in the DPPH radical- and galvinoxyl radical-scavenging assays. This selectivity suggests that ABG's antioxidant contribution is not equivalent to that of a general radical scavenger and is dependent on the reaction conditions.
Evidence strength: Weak to moderate for in vitro antioxidant effects. No human studies on antioxidant endpoints attributed specifically to ABG supplementation.
Ascorbigen is emerging as a significant immunomodulatory agent. Its immune effects are predominantly linked to AhR pathway activation, which modulates cytokine profiles and immune cell behavior. However, direct quantitative clinical evidence for ascorbigen-specific immunomodulation in humans is not established. Most available evidence is mechanistic and inferred from studies on the AhR pathway more broadly, or from studies on related compounds such as indole-3-carbinol and 3,3′-diindolylmethane.
Evidence strength: Weak. Mechanisms proposed are plausible based on AhR biology and related compound research, but dedicated human immunological trials for ABG specifically have not been published.
The primary route of human exposure to ascorbigen is dietary consumption of raw or fermented Brassica vegetables. Ascorbigen (ASG) is the most abundant indole-derived product in processed cruciferous vegetables, which humans and animals consume with food. It is formed in damaged plants or during food processing from alkaloid glucobrassicin transformation products and L-ascorbic acid.
Sauerkraut contains high levels of these anticarcinogenic compounds; however, their concentration depends on the conditions of the cabbage fermentation. Producing sauerkraut at low-salt concentration levels improved ascorbigen content, with the highest concentration being observed in lower sodium sauerkraut (0.5% NaCl) produced from cabbage cultivated in winter using natural fermentation.
Ascorbigen is the main glucosinolate hydrolysis product in fermented cabbage. Its stability at acidic pH makes fermented products a superior and more reliable dietary source of ABG than cooked Brassica vegetables.
Ascorbigen is not widely available as an isolated, standardized pharmaceutical supplement and has not been assigned an established daily recommended intake by any major regulatory or health body (such as the NIH Office of Dietary Supplements, EFSA, or WHO) as of the available literature. The following dosage information is drawn solely from what has been reported in the scientific literature.
This prompted the development of nutritional ingredients derived from these vegetables and their use as dietary supplements in different formulations which contain complete plant extracts or specific compounds. However, to date, standardized ABG-specific supplement products with documented dosage regimens supported by clinical evidence are not available.
Ascorbigen is consumed as part of the normal human diet through Brassica vegetables and fermented preparations, and at dietary exposure levels is considered safe as part of food. No specific adverse effects from dietary ABG intake have been documented in the peer-reviewed literature.
The most substantive safety concern raised in the scientific literature relates to the nature of ABG's gastric transformation products. The most important product of ascorbigen transformation in gastric juice is 5,11-dihydroindolo[3,2-b]-carbazole, with a binding affinity to the Ah receptor only 3.7 × 10−2 lower than that of tetrachlorodibenzodioxin. This compound may be responsible for modifying P450 enzyme activities.
This observation raises a theoretical concern: because this gastric acid metabolite is a relatively potent AhR ligand, it might — at pharmacologically elevated concentrations — produce biological effects analogous (though far weaker in absolute terms) to TCDD (a prototypical toxic dioxin). However, this metabolite has short metabolic persistence compared with halogenated dioxins, and at dietary exposure levels this concern is considered theoretical rather than demonstrated. The most important product of ascorbigen transformation in gastric juice is 5,11-dihydroindolo[3,2-b]-carbazole, with a binding affinity to the Ah receptor only 3.7 × 10−2 lower than that of tetrachlorodibenzodioxin, and this compound may be responsible for modifying P450 enzyme activities.
Similar AhR ligands exert variable anticancer or cancer-promoting potential in a cell- and tissue-specific mode of action. This means the net biological outcome of AhR activation by ABG-derived ligands is not universally protective and may depend on cell type, tissue context, existing disease state, and ligand concentration.
Because ABG and its metabolites can modulate cytochrome P450 enzyme activity — the compound produced in gastric juice may be responsible for modifying P450 enzyme activities — there exists a theoretical basis for drug interactions at pharmacological doses. Specifically, induction of CYP1A enzymes could potentially alter the metabolism of drugs that are substrates of these enzymes. This has not been demonstrated in human pharmacokinetic studies specific to ABG, and at dietary exposure levels is unlikely to be clinically significant, but remains a consideration at supplemental doses that substantially exceed dietary intake.
Comprehensive toxicological profiling of ascorbigen as an isolated supplement — including genotoxicity, reproductive toxicity, chronic toxicity, and interaction studies — has not been published in peer-reviewed form as of the available literature. The cytoprotective effects of ascorbigen may be highly relevant in the optimum physiological regulation of function, and the therapeutic value of this substance in disease settings needs to be further investigated. The absence of published toxicological data beyond in vitro and limited in vivo studies means that the safety profile of isolated ABG at pharmacological doses cannot be fully characterized.
Ascorbigen is a well-characterized natural compound from a chemical and biochemical perspective. Its presence in commonly consumed Brassica foods is established, its biosynthetic pathway is understood, and its in vitro biological activities — including antioxidant, antitumor, enzyme-modulating, vascular, and immunomodulatory effects — have been documented in peer-reviewed literature. Growing scientific evidence has suggested that consumption of cruciferous vegetables has a preventive role against a variety of human diseases.
However, isolating ABG's specific contribution to these effects — and establishing its efficacy as a stand-alone supplement at defined doses for specific health conditions — remains an open scientific question. The clinical evidence base is extremely thin: a single small open-label fibromyalgia study is the only direct human trial using an ABG-containing supplement published in peer-reviewed literature. All other evidence is preclinical (animal models or cell culture), mechanistic, or derived from epidemiology of Brassica food consumption. The anticarcinogenic action of isothiocyanates and indoles depends upon many factors, such as the test system, the target tissue, and the dose and chemical form in which they are presented — underscoring the difficulty of extrapolating from laboratory findings to clinical recommendations.
Health conditions that Ascorbigen may help support.
Body systems that Ascorbigen may help support.
Go back